ACIU · AC Immune SA
$2.49
-0.08 (-3.11%)
At close · Aug 14
Market Cap
$253.42M
Shares
101.77M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.49
Open$2.58
Day$2.43–2.58
52W close$2.04–3.99
Avg vol 30d211K
Short int3.6M · 3.5% float · 18.2d
Short vol49%
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−14%
below
Price vs 50-day avg
+5%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+13%
trailing
6-month return
−2%
trailing
YTD return
−21%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.49% of float · ▲ +4.6% MoM · 18.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−14%
Bearish
Price vs 50-day avg
+5%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.49% of float · ▲ +4.6% MoM · 18.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
43 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 23%
Range high $4
vs 200-day avg -14%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACIU
this stock
AC Immune SA
|
$253.42M | -20.7% | — | — | 3.5% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACIU | +5.5% | +13.2% | -1.6% | +13.7% | -20.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +5.1% | +8.7% | -15.4% | +9.8% | -34.6% |
Key facts
CIK
1651625
CUSIP
H00263105
13F (30d)
42 filings
41 filers
Visit website
Investor relations